A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT)

See ANZCTR for full trial details >

 

Trial Summary:

This study aims to develop a new treatment for glioblastoma (GBM), by finding out whether giving veliparib (an oral PARPi inhibitor drug) in combination with radiotherapy and follow up chemotherapy will improve the outcome of patients with unmethylated MGMT glioblastoma (GBM). The study will also find out how long the GBM responds to this treatment, the side effects of the treatment and the effect on quality of life.

Supported By:

Cure Brain Cancer Foundation; AbbVie; Cancer Council New South Wales (CCNSW) COGNO; NHMRC CTC

Eligibility:

Newly diagnosed patients with histologically confirmed GBM (WHO grade IV) following surgery, with unmethylated MGMT promoter gene.

Registration ID:

ACTRN12615000407594

Participation:

Australia

Australian Lead Group:

COGNO

Status:

 In follow up

Activation Date:

28/10/2015

Chairs:

A/Prof Mustafa Khasraw

Contact:

vertu.study@sydney.edu.au